Hcw Biologics (HCWB)CEO bought ~$160K
Hing C Wong, CEO at Hcw Biologics, bought ~$160K of Hcw Biologics shares.
- ~$160K
- Approx. value · 114K sh @ $1.41
- 616K
- Holds after · shares reported
- Traded
- May 22, 2026
- Filed
- May 27, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Mar 31, 2026Company filing · Form 8-K · ResultsReported its results
- Apr 15, 2026Company filing · Form 8-K · Bylaws or charterChanged its bylaws, charter or fiscal year
- May 14, 2026Company filing · Form 8-K · ResultsReported its results
- May 21, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 2 more items)
- May 21, 2026Company filing · Form 8-K · Agreement endedEnded an important agreement
- May 22, 2026 · this disclosureInsider · 3 insiders in a week, 7th time since 2021CEO purchased ~$160K of HCWB shares in the open market
What came next
- May 22, 2026Insider · 2 peopleInsiders: 2 purchases (~$270K)
- May 29, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“As previously disclosed, on March 26, 2026, HCW Biologics Inc. (the “Company”) received written notice from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) that for 30 consecutive business days, the Company’s listed securities did not maintain a minimum bid price of $1 per share, in accordance with Nasdaq Listing Rule 5550(a)(2) (“Bid Price Rule”) for continued listing on The…”
- Jun 24, 2026Company filing · Form 8-K · Shareholder rights, Bylaws or charterChanged the rights of its shareholders, and changed its bylaws, charter or fiscal year (and 1 more item)
- Jun 29, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On June 29, 2026, HCW Biologics Inc. (the “Company”) received written notice form the Listing Qualifications Staff (the “Staff”) of the Nasdaq Capital Market Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) found that the Company regained compliance with Listing Rule 5550(a)(2), the “Bid Price Rule,” per the terms set forth in the Panel’s decision letter dated May 29, 2026, as amended.”
- Jul 29, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 2 more items)
- Jul 29, 2026Insider · 3 peopleInsiders: 3 purchases (~$100K)
- Aug 10, 2026Company filing · Form 8-K · RestatementSaid past financial statements can no longer be relied on
- Aug 14, 2026Company filing · Form 8-K · ResultsReported its results
- Sep 4, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Hcw Biologics
For Hcw Biologics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its HCWB page.
Other recent filings by Hing C Wong, Chief Executive Officer
- SEC Form 4 at Hcw Biologics (HCWB)Jul 31, 2026
- SEC Form 4 at Hcw Biologics (HCWB)May 20, 2025
- SEC Form 4 at Hcw Biologics (HCWB)May 9, 2025
The full history of Hing C Wong, Chief Executive Officer is on the profile page.
How this filing works
Other disclosures at Hcw Biologics
- SEC Form 4Jul 31, 2026
- SEC Form 4Jul 31, 2026
- SEC Form 4Jul 31, 2026
- SEC Form 4May 27, 2026
- SEC Form 4May 27, 2026
- SEC Form 4May 20, 2025
Everything OQRO holds on this company is on its HCWB page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
